Patents by Inventor Nicholas D Kindon

Nicholas D Kindon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperazine derivatives as modulators of chemokine receptor activity
    Patent number: 6562825
    Abstract: The invention provides compounds of general formula (I) wherein R1, R2, R3, R4, R5, X, Y, Z, m and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: May 13, 2003
    Assignee: Astrazeneca UK Limited
    Inventors: Andrew J G Baxter, Stephen J Brough, Nicholas D Kindon, Thomas McInally, Bryan Roberts
  • N-alkyl-2-substituted ATP analogues for treatment of embolic disease conditions
    Patent number: 5955447
    Abstract: There are disclosed compounds of formula I, ##STR1## wherein R.sup.1 and R.sup.2 independently represent hydrogen or halogen, R.sup.3 and R.sup.4 independently represent phenyl, or alkyl C.sub.1-6 optionally substituted by one or more substituents selected from OR.sup.5, alkylthio C.sub.1-6, NR.sup.6 R.sup.7, phenyl, COOR.sup.8 and halogen,R.sup.5, R.sup.6, R.sup.7 and R.sup.8 independently represent hydrogen or alkyl C.sub.1-6, andX represents an acidic moiety,and pharmaceutically acceptable salts thereof. Processes for their production and pharmaceutical compositions and methods of treatment involving their use are also described.
    Type: Grant
    Filed: August 28, 1997
    Date of Patent: September 21, 1999
    Assignee: Astra Pharmaceuticals Limited
    Inventors: Anthony H Ingall, Peter A Cage, Nicholas D Kindon
  • N-alkyl-2-substituted ATP analogues and administration to inhibit platelet aggregation
    Patent number: 5721219
    Abstract: There are disclosed compounds of formula I, ##STR1## wherein R.sup.1 and R.sup.2 independently represent hydrogen or halogen, R.sup.3 and R.sup.4 independently represent phenyl, or alkyl C.sub.1-6, optionally substituted by one or more substituents selected from OR.sup.5, alkylthio C.sub.1-6, NR.sup.6 R.sup.7, phenyl, COOR.sup.8 and halogen,R.sup.5, R.sup.6, R.sup.7 and R.sup.8 independently represent hydrogen or alkyl C.sub.1-6, andX represents an acidic moiety,and pharmaceutically acceptable salts thereof. Processes for their production and pharmaceutical compositions and methods of treatment involving their use are also described.
    Type: Grant
    Filed: August 9, 1995
    Date of Patent: February 24, 1998
    Assignee: Astra Pharmaceuticals Ltd.
    Inventors: Anthony H. Ingall, Peter A. Cage, Nicholas D. Kindon